Inloggen

Login
 
Wachtwoord vergeten?

Aandeel ProQR Therapeutics NV OTC:PRQR, NL0010872495

  • 5,470 18 sep 2020 22:00
  • -0,070 (-1,26%) Dagrange 5,300 - 5,770
  • 70.126 Gem. (3M) 149,5K

AVA 2019

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
15 Posts
| Omlaag ↓
  1. forum rang 7 Tom3 21 mei 2019 20:18
    Zo dat was het dan weer voor dit jaar. In september weten we meer over Usher, kreeg de indruk dat men dit echt geheim wil houden. Maar gezien het aantal aandelen/opties dat het management zich heeft toebedeeld heeft men er alle vertrouwen in. Een lage uitoefenprijs (tgv de lage beurskoers) is natuurlijk ook niet verkeerd voor de heren/dame ontvangers. Wel een tegenslag was dat de samenwerking met Galapagos beëindigd is zonder resultaat en dat het Axiomer platform nog bewezen moet worden. Momenteel wordt Axiomer wel ingezet voor een nog te ontwikkelen rna medicijn. We gaan het zien.
  2. forum rang 7 Tom3 23 mei 2019 08:33
    quote:

    joel12 schreef op 22 mei 2019 12:21:


    what i find sort of interesting from the pipeline page www.proqr.com/pipeline/

    is that the cystic fibrosis product was completely removed.

    did they talk about this?


    Yes: too much competition for CF. The Huntington research will be paid by third parties (like DEB).
  3. joel12 23 mei 2019 14:42
    ok ya makes sense. for CF i cant imagine they are not planning to partner that out. cant imagine, about a year ago in a presentation the ceo said that many dont understand how valuable it is.
    but I had a question about Galapagos .. what is the status of the collaboration there? thanks Tom!
    btw, the Usher trial and results look promising, at least Proqr it is .. and next month is sponsoring an USHER event. around that time also presents at jmp just fyi.

    how where the spirits etc at the meeting?
  4. forum rang 7 Tom3 23 mei 2019 18:48
    quote:

    joel12 schreef op 23 mei 2019 14:42:


    ok ya makes sense. for CF i cant imagine they are not planning to partner that out. cant imagine, about a year ago in a presentation the ceo said that many dont understand how valuable it is.
    but I had a question about Galapagos .. what is the status of the collaboration there? thanks Tom!
    btw, the Usher trial and results look promising, at least Proqr it is .. and next month is sponsoring an USHER event. around that time also presents at jmp just fyi.

    how where the spirits etc at the meeting?


    Thanks for the Usher info. I assume this is in the US (will you attend this?). The collaboration with Galapagos has been terminated, no match?. Currently Axiomer is tested in 1 eye disease (pre-clinical research). News to be expected in 2020. Well officially the Usher trial is double blinded and only a very few seem to be informed. Rodman and Platenburg were in NY. So I have seen only poker faces. De Boer was so kind to admit that all patients in the LCA phase 1 trial have opted for treatment of their other eye: so this is a success. The fact that an Alnylam manager has been appointed in the board points to at least a decent future. I can`t imagine that she wants to join a company that is under too much stress. The second new board member is the present CFO from Galapagos. Interesting in case of a new secondary offering I would say.
  5. forum rang 7 Tom3 25 mei 2019 13:06
    quote:

    joel12 schreef op 24 mei 2019 19:04:


    ya the usher is in the US www.usher-syndrome.org/ush2019/progra...

    so you say that the collaboration w galapagos has been terminated? they said it or you think it has?

    thanks.. if you think of anything else interesting let me know.. btw proqr will be at JMP mid june to present.


    Wow, the Usher day(-s) in July is an important event for ProQR. By then the main findings from the ongoing trial should be known. Are you involved too in this terrible disease? Yes the termination has been communicated on the shareholders meeting. The final prove of Axiomer will not be delivered in 2019. Focus is on the rapid commercialization of the eye disease franchise as has been laid out in the winter. If this pans out as promised this stock could soar again.
  6. nmgn 12 juni 2019 13:33
    quote:

    joel12 schreef op 24 mei 2019 19:04:


    ya the usher is in the US www.usher-syndrome.org/ush2019/progra...

    so you say that the collaboration w galapagos has been terminated? they said it or you think it has?

    thanks.. if you think of anything else interesting let me know.. btw proqr will be at JMP mid june to present.


    Dit event lijkt me nu de uitgelezen plek om de resultaten van Stellar te bespreken en te doorgronden. Die worden "mid 2019" bekend gemaakt. Ik neem aan dat intern de resultaten nu wel duidelijk zijn. Dus laten we zeggen ergens begin juli het persbericht met goede resultaten? Of zouden ze daar als silver sponsor gaan staan zonder resultaten of met slechte resultaten?
15 Posts
|Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

ProQR Therapeutics NV Meer »

Koers 5,470   Verschil -0,07 (-1,26%)
Laag 5,300   Volume 70.126
Hoog 5,770   Gem. Volume 149.540
18 sep 2020 22:00
label premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare